| You
are here: Home: BCU 6|2003: Joyce
O’Shaughnessy, MD: Select publications
Select publications
Publications discussed by Dr O’Shaughnessy
Euler U et al. Dose and time intensified epirubicin/cyclophosphamide
(EC) as preoperative treatment in locally and advanced breast cancer. Breast
Cancer Res Treat 2002; Abstract
154.
O'Shaughnessy J et al. Superior survival with capecitabine
plus docetaxel combination therapy in anthracycline-pretreated
patients
with advanced breast cancer: Phase III trial results. J Clin Oncol
2002;20(12):2812-23. Abstract
Sledge GW et al. Phase III trial of doxorubicin, paclitaxel,
and the combination of doxorubicin and paclitaxel as front-line
chemotherapy for metastatic breast cancer: An intergroup trial
(E1193). J Clin Oncol 2003;21(4):588-92. Abstract
Combination versus sequential chemotherapy in the treatment of
metastatic breast cancer
Ahn Sr, JH et al. Phase II study of combination chemotherapy
of capecitabine and vinorelbine in metastatic breast cancer with
previous exposure to anthracycline and taxane: Preliminary results. Proc ASCO 2002;Abstract
2030.
Alba E et al. Multicenter phase III randomized trial
comparing sequential versus concomitant administration of doxorubicin
(A)
and docetaxel (T) as first-line treatment of metastatic breast
cancer (MBC). GEICAM 9903 Study. Proc ASCO 2003; Abstract
27.
Crown J et al. Chemotherapy for metastatic breast cancer — report
of a European expert panel. Lancet Oncol 2002;3(12):719-27. Abstract
Domenech G et al. Vinorelbine/capecitabine (VINOCAP)
combination remission induction therapy for metastatic breast
cancer (MBC). Proc ASCO 2001; Abstract 1939.
Ghosn M et al. Vinorelbine (Navelbine) IV and capecitabine
(vinocap) as front line chemotherapy in metastatic breast cancer
(MBC). Proc
ASCO 2002;Abstract
1978.
Hudis CA. Single-agent vs combination therapy in advanced
breast cancer: Potential roles of capecitabine. Oncology (Huntingt) 2002;16(10
Suppl 12):13-6. Abstract
Miles D et al. Combination versus sequential single-agent
therapy in metastatic breast cancer. Oncologist 2002;7(Suppl
6):13-9. Erratum
in: Oncologist 2003;8(1):127. Abstract
Nabholtz JM et al. Combination chemotherapy for metastatic
breast cancer. Expert Rev Anticancer Ther 2002;2(2):169-80. Abstract
O'Shaughnessy J et al. Superior survival with capecitabine
plus docetaxel combination therapy in anthracycline-pretreated
patients
with advanced breast cancer: Phase III trial results. J Clin Oncol
2002;20(12):2812-23. Abstract
Paridaens R et al. A randomized phase II study of alternating
and sequential regimens of docetaxel and doxorubicin as first-line
chemotherapy for metastatic breast cancer. Ann Oncol 2003;14(3):433-40.
Abstract
Perez EA et al. A randomized phase II study of sequential
docetaxel and doxorubicin/cyclophosphamide in patients with metastatic
breast
cancer. Ann Oncol 2002;13(8):1225- 35. Abstract
Rossi A et al. Single agent vinorelbine as first-line
chemotherapy in elderly patients with advanced breast cancer. Anticancer Res
2003;23(2C):1657-64. Abstract
Seidman AD. Monotherapy options in the management of
metastatic breast cancer. Semin Oncol 2003;30(2 Suppl 3):6-10. Abstract
Seidman AD et al. Single-agent capecitabine: A reference
treatment for taxane-pretreated metastatic breast cancer? Oncologist 2002;7
Suppl 6:20-8. Abstract
Sledge GW et al. Phase III trial of doxorubicin, paclitaxel,
and the combination of doxorubicin and paclitaxel as front-line
chemotherapy for metastatic breast cancer: An intergroup trial
(E1193). J Clin Oncol 2003;21(4):588-92. Abstract
Talbot DC et al. Randomised, phase II trial comparing
oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced
breast
cancer pretreated with anthracyclines. Br J Cancer 2002;86(9):1367-72.
Abstract
Tripathy D. Overview: Gemcitabine as single-agent therapy
for advanced breast cancer. Clin Breast Cancer 2002;3 Suppl 1:8-11.
Abstract
Van Poznak C, Seidman AD. Critical review of current
treatment strategies for advanced hormone insensitive breast
cancer. Cancer
Invest 2002;20 Suppl 2:1-14. Abstract
Zimatore M et al. Weekly taxanes in metastatic breast
cancer. Oncol Rep 2002;9(5):1047-52. Abstract
|
